US regulators approved Moderna Inc.’s Covid vaccine for children, but for a narrower group than before, continuing Robert F.

The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...

Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / ...

Moderna (MRNA) stock rises as the company's Spikevax COVID-19 vaccine gets FDA approval for kids 6 months-11 years at higher ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

Moderna's Spikevax was previously available for paediatric populations under emergency use authorisation. Moderna expects to make its updated vaccine available for eligible  US population for the 2025 ...

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Intense throat pain is a key symptom of COVID-19 variant NB.1.8.1, referred to as "razor blade throat." Here's what to know.

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...